Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the Freenome Multiomics Blood Test as a new way to screen for lung cancer in people at high risk. This observational study includes adults aged 50 and older who are current or former smokers with a significant smoking history. The goal is to see how well this blood test works alongside the standard Low-Dose Computed Tomography LDCT screening to detect lung cancer early. Participants will provide a blood sample of 50 ml that will be tested and stored by Freenome or its designee. They will also undergo a standard LDCT chest scan, ideally on the same day as the blood draw or within 45 days afterward. The study collects additional information such as medical history, lifestyle, environmental exposures, and results from diagnostic tests related to lung cancer detection. Participants will be monitored for at least 24 months following their baseline chest CT scan to track health outcomes. Researchers will review clinical data, imaging reports, and lab results during this period. The main outcome measured is the blood tests sensitivity and specificity in detecting lung cancer at 12 months, with additional measurements at 24 months. The study may end early if participants withdraw or pass away.
Actively Recruiting
Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.
Actively Recruiting
Researchers are evaluating two different ways to deliver the Otago Exercise Program OEP, an exercise plan designed to reduce falls and related injuries in older adults. This study focuses on community-dwelling adults aged 55 and older who are at intermediate or high risk of falling. The aim is to compare the effectiveness and user experience of a smartphone-based home program versus an in-person community program. Participants will be randomly assigned to one of two groups a remotely delivered, smartphone-based OEP or an in-person group program held at a senior center. Each group receives sixteen individualized 60-minute training sessions over eight weeks, focusing on balance, mobility, and strength exercises. The smartphone group uses an app to track exercises and receives weekly phone support, while the community group exercises together under physical therapy student supervision. Before and after the program, participants complete surveys and physical tests measuring balance, walking speed, strength, and confidence in avoiding falls. Gait speed is also monitored weekly via the smartphone app during the study. The research team will assess these outcomes to understand which delivery method better supports fall prevention. The total participation time is approximately nine weeks including baseline and post-training assessments.
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
Healthy Volunteer
Researchers are studying how infants of mothers with postpartum major depression develop attentional biases toward emotional facial expressions. The study aims to understand these attentional patterns as a possible risk mechanism and to explore how infant arousal might influence these biases. This research focuses on infants and their mothers, specifically examining early emotional and attentional development in the context of maternal depression. Infants will participate in a computer-based task where they view facial expressions showing anger, happiness, sadness, or neutrality while an eye tracker records their gaze. Both mothers and infants will also engage in a structured interaction task consisting of three stages two free play periods and a sad interaction where mothers are asked to express minimal engagement. Each stage lasts three minutes, allowing assessment of infant gaze and physiological responses. Participants will be assessed at baseline and followed up at 3, 6, 9, and 12 months. During these visits, researchers will measure infants eye gaze during both the computer and interaction tasks, as well as infant heart rate and respiratory sinus arrhythmia. Social-emotional development will also be monitored over time. The study involves observing infant behavior and physiological responses to better understand emotional attention development in the context of maternal depression.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Healthy Volunteer
Underage drinking is a significant issue in the United States, with many high school students using alcohol and facing negative consequences such as academic problems, impaired functioning, and risky behaviors. This research aims to test the effectiveness of two web-based interventions, the e-CHECKUP TO GO eCTG alone and combined with an electronic Parent-Based Intervention ePBI, in reducing alcohol use among high school juniors and seniors. The study uses a nationally representative sample to address the limited interventions available for older high school students. Participants are randomly assigned to one of four groups the eCTG program, the combined eCTGePBI program, the e-Parent Intervention alone, or a control group receiving no intervention. The eCTG provides personalized feedback about alcohol use and risks, while the e-Parent Intervention offers an electronic handbook to guide parents in discussing drinking with their teens. Data are collected over five waves including baseline, and 3-, 6-, 9-, and 12-month follow-ups, with one wave involving parents at 3 months. During the study, participants and their parents complete assessments on alcohol use and consequences at multiple time points. Researchers measure changes in alcohol consumption and related negative outcomes throughout the year. The studys goal is to evaluate how these digital interventions affect drinking behavior and reduce harm. Participation involves completing surveys and using the web programs as assigned, with ongoing monitoring of outcomes up to 12 months.
Actively Recruiting
Researchers are investigating maridebart cafraglutide for people with obesity or overweight to evaluate its long-term effects on weight management, safety, and tolerability. This trial is an extension of a previous study trial 20210181 and aims to provide more information about how the drug works over an extended period. It is a phase 3, randomized, double-blind study sponsored by Amgen. Participants will receive different doses of maridebart cafraglutide or placebo depending on their treatment in the previous trial. Some will continue with low dose every 4 weeks, others will be re-randomized to receive medium or high doses on schedules of every 4, 8, or 12 weeks, or placebo injections every 4 weeks. Participants who had placebo before will undergo a dose-escalation phase before starting the high dose treatment. During the study, participants will be monitored for changes in body weight, waist circumference, quality of life, and any side effects or adverse events over about 48 weeks of treatment. The trial will assess how well weight loss is maintained and record any treatment-emergent adverse events up to 60 weeks. Participants will have regular visits for injections and safety assessments throughout the study period.
Actively Recruiting
Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.
Actively Recruiting
Researchers are conducting the FLEX Registry, a large-scale, population-based study focusing on patients with stage I to III breast cancer who have undergone MammaPrint and BluePrint testing on their primary breast tumors. This observational registry aims to gather comprehensive full genome expression data linked with clinical information to explore new gene associations that may have prognostic or predictive value. The design is adaptive, allowing additional targeted substudies and arms to be added over time for more specific investigations. All participants will have their tumor samples tested using MammaPrint and BluePrint through the full-genome testing array provided by Agendia. Treatment decisions are made by the treating physician following NCCN guidelines or recognized alternatives, with no specific treatment mandated by the study. The registry plans to enroll about 30,000 patients from more than 125 US institutions, encompassing various treatment arms detailed in study appendices. Participants will have clinical data collected online at multiple time points at enrollment, during treatment, and at 1, 3, 5, and 10 years after diagnosis. This long-term follow-up allows researchers to study gene expression alongside clinical outcomes, supporting the creation of subgroup analyses and future targeted trials. The primary outcomes include establishing a large-scale full genome expression registry and providing infrastructure for examining smaller patient groups over the 10-year study period.
1-10 of 16
1